TICKERNOMICS Sign up
Last Update: 2024-03-28 02:09:47
Penumbra Inc ( PEN ) https://www.penumbrainc.com
220.87USD
Sector:
Healthcare
Industry:
Medical Devices
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-19.84%
PEN
SPY
32.74%
-16.01%
PEN
SPY
92.93%
PEN
50.24%
SPY
224.41%
PEN
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
8513.42
8573.76
0.93
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
93.60
8.04
7.22
0.81
0.00
119.54
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
4.66
65.69
6.78
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
6.9183
9.35
3.84
0.71
Other Earnings and Cash Flow Stats:
Penumbra Inc ( PEN ) Net Income TTM ($MM) is 85.62
Penumbra Inc ( PEN ) Operating Income TTM ($MM) is 17.88
Penumbra Inc ( PEN ) Owners' Earnings Annual ($MM) is 50.63
Penumbra Inc ( PEN ) Current Price to Owners' Earnings ratio is 168.75
Penumbra Inc ( PEN ) EBITDA TTM ($MM) is 44.06
Penumbra Inc ( PEN ) EBITDA Margin is 6.78%
Capital Allocation:
Penumbra Inc ( PEN ) has paid 0.00 dividends per share and bought back -0.839675 million shares in the past 12 months
Penumbra Inc ( PEN ) has reduced its debt by 64.159 million USD in the last 12 months
Capital Structure:
Penumbra Inc ( PEN ) Interest-bearing Debt ($MM) as of last quarter is 208
Penumbra Inc ( PEN ) Annual Working Capital Investments ($MM) are -5
Penumbra Inc ( PEN ) Book Value ($MM) as of last quarter is 1178
Penumbra Inc ( PEN ) Debt/Capital as of last quarter is 17%
Other Balance Sheet Stats:
Penumbra Inc ( PEN ) has 167 million in cash on hand as of last quarter
Penumbra Inc ( PEN ) has 151 million of liabilities due within 12 months, and long term debt 23 as of last quarter
Penumbra Inc ( PEN ) has 38 common shares outstanding as of last quarter
Penumbra Inc ( PEN ) has 0 million USD of preferred stock value
Academic Scores:
Penumbra Inc ( PEN ) Altman Z-Score is 15.02 as of last quarter
Penumbra Inc ( PEN ) Piotroski Score is 8.00 as of last quarter
Corporate Governance:
Penumbra Inc ( PEN ) largest shareholder is HHG PLC owning 270483 shares at 59.74 ($MM) value
Arani Bose(an insider) Sold 7500 shares of Penumbra Inc ( PEN ) for the amount of $1876500.00 on 2024-03-04
3.90% of Penumbra Inc ( PEN ) is held by insiders, and 92.50% is held by institutions
Penumbra Inc ( PEN ) went public on 2015-09-18
Other Penumbra Inc ( PEN ) financial metrics:
FCF:15.26
Unlevered Free Cash Flow:122.98
EPS:5.61
Operating Margin:4.66
Gross Profit Margin:65.69
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:18.40
Beta:0.71
Buffet's Owners Earnings:50.63
Price to Owner's Earnings:168.75
About Penumbra Inc ( PEN ) :
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and POD (Penumbra Occlusion Device) brand, as well as immersive 3D computer-based technology platform under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.